ESR1 and breast cancer: Tamoxifen, one of the most commonly administered SERMs, competes with estradiol, a major estrogen sex hormone for ER binding, to function as a partial ER antagonist and a transcriptional inhibitor of estrogen-responsive genes, thereby inhibiting breast cancer growth.